The widespread use of next generation sequencing for clinical testing is detecting an escalating number of variants in noncoding regions of the genome. The clinical significance of the majority of these variants is currently unknown, which presents a significant clinical challenge. We have screened over 6,000 early-onset and/or familial breast cancer (BC) cases collected by the ENIGMA consortium for sequence variants in the 5' noncoding regions of BC susceptibility genes BRCA1 and BRCA2, and identified 141 rare variants with global minor allele frequency < 0.01, 76 of which have not been reported previously. Bioinformatic analysis identified a set of 21 variants most likely to impact transcriptional regulation, and luciferase reporter assays detected altered promoter activity for four of these variants. Electrophoretic mobility shift assays demonstrated that three of these altered the binding of proteins to the respective BRCA1 or BRCA2 promoter regions, including NFYA binding to BRCA1:c.-287C>T and PAX5 binding to BRCA2:c.-296C>T. Clinical classification of variants affecting promoter activity, using existing prediction models, found no evidence to suggest that these variants confer a high risk of disease. Further studies are required to determine if such variation may be associated with a moderate or low risk of BC.

• MeSH
• 5' nepřekládaná oblast MeSH
• aktivátorový protein specifický pro B-buňky metabolismus   MeSH
• faktor vázající CCAAT metabolismus   MeSH
• genetická predispozice k nemoci MeSH
• lidé MeSH
• MFC-7 buňky MeSH
• nádorové buněčné linie MeSH
• nádory prsu genetika   MeSH
• promotorové oblasti (genetika) * MeSH
• protein BRCA1 chemie   genetika   metabolismus   MeSH
• protein BRCA2 chemie   genetika   metabolismus   MeSH
• vazba proteinů MeSH
• věk při počátku nemoci MeSH
• zárodečné mutace * MeSH
• Check Tag
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Topoisomerase IIalpha (topo IIalpha) is a nuclear enzyme involved in several critical processes, including chromosome replication, segregation and recombination. Previously we have shown that chromosomal protein HMGB1 interacts with topo IIalpha, and stimulates its catalytic activity. Here we show the effect of HMGB1 on the activity of the human topo IIalpha gene promoter in different cell lines. We demonstrate that HMGB1, but not a mutant of HMGB1 incapable of DNA bending, up-regulates the activity of the topo IIalpha promoter in human cells that lack functional retinoblastoma protein pRb. Transient over-expression of pRb in pRb-negative Saos-2 cells inhibits the ability of HMGB1 to activate the topo IIalpha promoter. The involvement of HMGB1 and its close relative, HMGB2, in modulation of activity of the topo IIalpha gene is further supported by knock-down of HMGB1/2, as evidenced by significantly decreased levels of topo IIalpha mRNA and protein. Our experiments suggest a mechanism of up-regulation of cellular expression of topo IIalpha by HMGB1/2 in pRb-negative cells by modulation of binding of transcription factor NF-Y to the topo IIalpha promoter, and the results are discussed in the framework of previously observed pRb-inactivation, and increased levels of HMGB1/2 and topo IIalpha in tumors.

• MeSH
• aktivace transkripce MeSH
• antigeny nádorové biosyntéza   genetika   MeSH
• DNA vazebné proteiny biosyntéza   genetika   MeSH
• DNA-topoisomerasy typu II biosyntéza   genetika   MeSH
• DNA chemie   metabolismus   MeSH
• faktor vázající CCAAT metabolismus   MeSH
• financování organizované MeSH
• lidé MeSH
• mutageneze MeSH
• nádorové buněčné linie MeSH
• promotorové oblasti (genetika) MeSH
• protein HMGB1 genetika   chemie   metabolismus   MeSH
• protein HMGB2 metabolismus   MeSH
• retinoblastomový protein metabolismus   MeSH
• senioři MeSH
• upregulace MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH